These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 12197319)

  • 1. Using X-ray crystallography in drug discovery.
    Rowland RS
    Curr Opin Drug Discov Devel; 2002 Jul; 5(4):613-9. PubMed ID: 12197319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From virtuality to reality - Virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective.
    Rester U
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):559-68. PubMed ID: 18600572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystallography, NMR and virtual screening: integrated tools for drug discovery.
    Muchmore SW; Hajduk PJ
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):544-9. PubMed ID: 12951817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput X-ray crystallography for drug discovery.
    Blundell TL; Patel S
    Curr Opin Pharmacol; 2004 Oct; 4(5):490-6. PubMed ID: 15351354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput protein crystallography and drug discovery.
    Tickle I; Sharff A; Vinkovic M; Yon J; Jhoti H
    Chem Soc Rev; 2004 Oct; 33(8):558-65. PubMed ID: 15480479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-guided fragment screening for lead discovery.
    Verdonk ML; Hartshorn MJ
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):404-10. PubMed ID: 15338949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of ribosomal crystal structures in antibiotic drug design.
    Wimberly BT
    Curr Opin Investig Drugs; 2009 Aug; 10(8):750-65. PubMed ID: 19649920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
    Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational approaches to natural-product-based drug design.
    Haustedt LO; Mang C; Siems K; Schiewe H
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):445-62. PubMed ID: 16889228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design of molecular cancer therapeutics.
    van Montfort RL; Workman P
    Trends Biotechnol; 2009 May; 27(5):315-28. PubMed ID: 19339067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors.
    Qiao L; Baumann CA; Crysler CS; Ninan NS; Abad MC; Spurlino JC; Desjarlais RL; Kervinen J; Neeper MP; Bayoumy SS; Williams R; Deckman IC; Dasgupta M; Reed RL; Huebert ND; Tomczuk BE; Moriarty KJ
    Bioorg Med Chem Lett; 2006 Jan; 16(1):123-8. PubMed ID: 16236500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design.
    Davis AM; Teague SJ; Kleywegt GJ
    Angew Chem Int Ed Engl; 2003 Jun; 42(24):2718-36. PubMed ID: 12820253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment-based drug design: combining philosophy with technology.
    Bartoli S; Fincham CI; Fattori D
    Curr Opin Drug Discov Devel; 2007 Jul; 10(4):422-9. PubMed ID: 17659483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent trends in library design: 'rational design' revisited.
    Schnur DM
    Curr Opin Drug Discov Devel; 2008 May; 11(3):375-80. PubMed ID: 18428091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Industrial perspective on X-ray data collection and analysis.
    Skarzynski T; Thorpe J
    Acta Crystallogr D Biol Crystallogr; 2006 Jan; 62(Pt 1):102-7. PubMed ID: 16369099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Affinity-based screening techniques for enhancing lead discovery.
    Comess KM; Schurdak ME
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):411-6. PubMed ID: 15338950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors.
    Vulpetti A; Casale E; Roletto F; Amici R; Villa M; Pevarello P
    J Mol Graph Model; 2006 Mar; 24(5):341-8. PubMed ID: 16260160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designer drugs: the evolving science of drug discovery.
    Wanke LA; DuBose RF
    Pharm Pract Manag Q; 1998 Jul; 18(2):13-22. PubMed ID: 10185235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solid-phase compound library synthesis in drug design and development.
    Edwards PJ; Morrell AI
    Curr Opin Drug Discov Devel; 2002 Jul; 5(4):594-605. PubMed ID: 12197317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A decade of fragment-based drug design: strategic advances and lessons learned.
    Hajduk PJ; Greer J
    Nat Rev Drug Discov; 2007 Mar; 6(3):211-9. PubMed ID: 17290284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.